Skip to Content

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

Pemigatinib – an oral FGFR1-3 inhibitor has shown efficacy and safety in patients with advanced/metastatic cholangiocarcinoma. In this MEDtalk Abou-Alfa K. Ghassan presents the updated FIGHT-202 study published in the Lancet Oncology, where overall survival for responders was more than twice as long vs for non-responders

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top